What is the growth potential of the life sciences sector in Quebec and Canada? What is the true contribution of the innovative pharmaceutical industry to the Canadian economy? What are the trends and opportunities for public-private partnerships in pharmaceutical research? Can Montreal take advantage of the opportunities related to the application artificial intelligence in the life sciences sector? How can we improve provincial and federal public policies to capture the full potential of the life sciences sector?
Pamela Fralick, President of Innovative Medicines Canada, and panelists will discuss these important issues as well as the results of Fall 2017 EY analysis of the economic contribution of Canada's innovative pharmaceutical industry. They will also examine ways in which the pharmaceutical industry along with the Government of Quebec and the Government of Canada can work together to find solutions that provide equitable, affordable and faster access to new therapies while contributing to the development of the life sciences sector in Canada.